MITA shows support of Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018

The Medical Imaging & Technology Alliance (MITA) has issued a statement in support of the recently introduced Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018 (HR 6948).

The legislation, which would recognize radiopharmaceuticals as drugs in Medicare’s Hospital Outpatient Prospective Payment System (HOPPS) and ensure they maintain pass-through status, was introduced by U.S. Reps. George Holding (R-North Carolina) and Seth Moulton (D-Massachusetts).

According to MITA, the bill would improve patient access to radiopharmaceuticals they need to receive the best care possible.

“This legislation will allow essential radiopharmaceuticals to be accurately considered as drugs and paid separately in the Medicare hospital outpatient setting,” Bill Abbott, chair of the MITA PET Group, said in a prepared statement. “Passage of this legislation will remove the disincentive to innovation and contribute to greater patient access to these important diagnostic tests.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The ACR hopes these changes, including the addition of diagnostic performance feedback, will help reduce the number of patients with incidental nodules lost to follow-up each year.

And it can do so with almost 100% accuracy as a first reader, according to a new large-scale analysis.

The patient, who was being cared for in the ICU, was not accompanied or monitored by nursing staff during his exam, despite being sedated.